Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization

In order to evaluate the effect of topical and subconjunctival anti-vascular endothelial growth factor (anti-VEGF) therapy, Ranibizumab, Bevacizumab and Aflibercept as a therapy for corneal neovascularization (NV) treatment, the aim of this study was to review all data related to some of anti-VEGF a...

Full description

Bibliographic Details
Main Authors: Tariq Al-Debasi, Abdulkareem Al-Bekairy, Abdulmalik Al-Katheri, Shmeylan Al Harbi, Mahmoud Mansour
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-04-01
Series:Saudi Journal of Ophthalmology
Subjects:
Anti-VEGF
Bevacizumab
Ranibizumab
Aflibercept
Cornea
Online Access:http://www.sciencedirect.com/science/article/pii/S1319453417300310

Internet

http://www.sciencedirect.com/science/article/pii/S1319453417300310

Similar Items